Table 1.
Performance of Bladder Epicheck test among studies.
| Studies | BE Results Considered for the Statistical Analysis |
NMIBC Recurrences Prevalence | Sensitivity | Specificity | PPV | NPV | ||
|---|---|---|---|---|---|---|---|---|
| All Grades | non-LG | All Grades | non-LG | |||||
| Wasserstrom et al. (2016) | 222 | 18% | 90% | 95% | 83% | - | 97% | - |
| Witjes et al. (2018) | 353 | 12.5% | 68.2% | 88.9% | 88% | 44.8% | 95.1% | 99.3% |
| Lozano et al. (2019) | 657 | 12.2% | 62.5% | 86.4% | 85.8% | - | 94.3% | 98.8% |
| D’Andrea et al. (2019) | 357 | 13.7% | 67.3% | 89% | 88% | 47% | 94% | 99.3% |
| Trenti et al. (2019) | 215 | 32.1% | 62.3% | 83.3% | 86.3% | 68.2% | 82.9% | - |
| Righetto et al. (2019) | 72 | 29.2% | 76.2% | 100% | 90.2% | 76.2% | 97.4% | 100% |
| Trenti et al. (2020) | 432 | 21.3% | 64.1% | 78.9% | 82.1% | 49.1% | 89.4% | - |
NMIBC: non-muscle-invasive bladder cancer; BE: Bladder EpiCheck test; PPV: positive predictive value; NPV: negative predictive value; LG: low-grade bladder cancers.